To Bleed Or Not To Bleed: Questioning the Biomedical Construct of Menopause by Dol, Christine
Totem: The University of Western Ontario Journal of
Anthropology
Volume 13 | Issue 1 Article 6
6-21-2011
To Bleed Or Not To Bleed: Questioning the
Biomedical Construct of Menopause
Christine Dol
The University of Western Ontario
Follow this and additional works at: http://ir.lib.uwo.ca/totem
Part of the Social and Cultural Anthropology Commons
This Article is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Totem: The University of Western
Ontario Journal of Anthropology by an authorized administrator of Scholarship@Western. For more information, please contact kmarsha1@uwo.ca.
Recommended Citation
Dol, Christine (2005) "To Bleed Or Not To Bleed: Questioning the Biomedical Construct of Menopause," Totem: The University of
Western Ontario Journal of Anthropology: Vol. 13: Iss. 1, Article 6.
Available at: http://ir.lib.uwo.ca/totem/vol13/iss1/6
To Bleed Or Not To Bleed: Questioning the Biomedical Construct of
Menopause
Keywords
menopause, biomedical construct, disease
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0
License.
This article is available in Totem: The University of Western Ontario Journal of Anthropology: http://ir.lib.uwo.ca/totem/vol13/
iss1/6
To Bleed Or Not To Bleed?
Questioning the Biomedical Construct
of Menopause
What is menopause? This question is more
complicated than it appears. Menopause is both
a biological process and a cultural event in most
societies around the world. All women, if they
live long enough will eventually stop
menstruating. The cessation of menses is
experienced by women differently according to
their outlook on life, their self-esteem, their
nutritional status, their general health and their
customary practices. Anthropologists who have
studied the diversity of cultural experiences
regarding this biological aging process suggest
that menopause is a social construct differently
perceived and exhibited in different cultures.
The most significant fmd of these studies
suggests, "that menopause is most remarkable
for being unremarkable" (Davis 1996:68). There
is no one typical, universal, menopausal woman.
Western "medicine is not interested in
the cessation of menses per se", but in the
underlying hormonal changes associated with
"the aging process during which a woman passes
from a reproductive to a nonreproductive stage"
(Davis 1996:68). Since the end of 1960s,
doctors have been prescribing hormone
replacement therapy to women for a multitude of
physical symptoms related to the ideological
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construct of menopause as a disease. The list of
disease manifestations representative of
menopause is a rather fluid concept which has
been continually reinvented based on the latest
scientific studies throughout the century. In
North America, drug therapy has become the
medical and culturally acceptable treatment for
women in mid-life experiencing vasomotor
symptoms, such as hot flashes, and as a
prophylactic measure to prevent a host of
diseases. The concept of women's bodies as a
diseased body has become so successful that
menopause has been turned into a billion dollar a
year industry (Fausto-Sterling 1999).
Recently, the Western biomedical
construct of menopause as an 'estrogen
deficiency disease' has come under fue as the
harmful results of the hormone replacement
study carried out by the Women's Health
Initiative have been reported. Over the last two
years, numerous studies coming from this
research suggest that the risk of hormone
replacement therapy (HR T) outweigh the
benefits. In fact, many of these results
contradict most of the fundamental biomedical
paradigms which promote HRT as a suitable
'treatment' for women during mid-life. The
stark realization that HRT may be detrimental to
women's health has caused an explosion of
biomedical discourse surrounding menopause.
This proliferation of medical information
available to women on-line and through medical
health agencies is designed to educate women
about their bodies and attempts to clarify the pros
and cons of HRT. The latest pharmaceutical
information available to women regarding HRT
suggests that the lowest possible dose for the
shortest duration of time, continues to be a
suitable option and important treatment for the
physical manifestations of menopause.
The medical construction of menopause
as a disease of the female body continues to be
the site of contention: a struggle between a
paradigm shift in understanding women's bodily
changes during mid-life as a positive process,
and the socio/politicaUeconomic interests which
are dependant on maintaining the status quo in
patriarchal gender domination. This essay will
briefly outline the history of the biomedical
construct of menopause since Victorian times in
order to shed some light on understanding how
certain disease processes became attributed to
menopause. Medical assumptions and forms of
treatment will be examined in relation to the
wider global perspective of political, economical
and social changes that affect women in
America. I will argue that the surge of
biomedical discourse after the Women's Health
Initiative hormone replacement study reinforces
the menopause myth and reinscribes the female
body as the diseased body to be monitored,
regulated and medicated as a form of socio-
economic and political control.
Once upon a Victorian Time .
Medical discoveries of biological
processes have changed the way menopause as a
medical issue has evolved throughout the
century. In her essay, "Meno-Boomers and
Moral Guardians", Joy Webster Barbre examines
the contemporary biomedical model of
menopause as a cultural construct by juxtaposing
Victorian medical and cultural assumptions
regarding women's bodies, menopause and aging
against current ideologies (Barbre 2003). Over
one hundred years ago as science replaced
religion as the prime shaper of cultural values in
the search for objective truth, the discipline of
medicine became established as the knowers of
the known female body. It was at this time that
medical language became authoritarian,
recognized by both speaker and listener as
rational discourse and empirical truth (Foucault
1994). The nineteenth century medical theory
regarding the female body suggested that, "a
woman's reproductive organs governed her
entire being; they dictated her personality, her
abilities and limitations, and hence her social
role" (Barbre 2003:272). Women's subjectivity
was medically constructed around reproductive
functions; either bleeding and breeding or
wasting and withering. Menopause was
perceived as a time of reproductive failure,
central nervous system disturbances, moral
insanity and a host of various physical and
psychological maladies. Menopause "was
fraught with danger ... the prescriptive model for
surviving those dangers ...stressed and reinforced
the delicate, nurturing, and moral qualities
assumed to be a part of Victorian womanhood
..." (Barbre 2003:278). In the Late Victoria
times, women's bodies were prone to failing,
unlike their minds which were habitually prone
to disease.
The Menopause Myth Reconfigured
Michel Foucault argued that, "Disease,
like the word, is deprived of being, but, like the
word, it is endowed with a configuration"
(Foucault 1994: 119). The power of naming this
thing called menopause as an 'estrogen
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deficiency disease' to be cured with hormone
replacement therapy was fust framed in 1966 by
Dr. Robert A Wilson. In his so-called 'best
seller', Feminine Forever, Wilson proclaimed
that with continuous estrogen ingestion,
"menopause is curable menopause is
completely preventable ... Instead of being
condemned to witness the death of their own
womanhood ... [women] will remain fully
feminine - physically and emotionally - for as
long as they live" (Wilson cited in Barbre
2003 :279). The language of menopause was
engulfed in failure; declining hormones,
withering ovaries, vaginal atrophy, diminished
capacity and senility. Emily Martin suggested
that Wilson's authoritative emphasis on the
"negative aspects of ovaries failing to produce
female hormones", created the image of women
in mid-life as a time of 'system failure' when the
female body would experience "regression,
decline, atrophy, shrinkage and disturbances"
(Martin 1997:26-27). Women's bodies would
collapse like old dilapidated machines without
oil and grease to keep the parts in working order
(Martin 1997).
The central theme of the menopause
myth was the notion that since every aging
woman would eventually stop menstruating only
to endure debilitating health, it was reasoned that
all women regardless of class, sexual preference,
occupation, race, and physical condition were, or
would be, potential candidates for
pharmaceutical products to control their failing,
diseased bodies. By seeming concerned over
the health of women's bodies and minds,
biomedical discourse concentrated on fmding
solutions to the 'woman problem'. Margaret
Lock argued, "however, this apparent concern
for the welfare of society is, in many cases, a thin
disguise for a vested interest in the potential
profit that is to be made by attempting to keep
women healthy" (Lock 1993 :335). The
manufacture, promotion, and sales of estrogen
sky-rocketed right through the mid 1970s,
making HRT among the top five pharmaceutical
sales in North America (Fausto-Sterling 1999).
Anne Fausto-Sterling writes, "the 'disease of
menopause' is not only a social problem: it's big
business" (Fausto-Sterling 1999: 170).
Myths within the Myth
The empty nest syndrome was the fust
spin-off from the menopause myth. Similar to
Victorian times, it was believed that menopause
continued to cause major psychological problems
for aging women. Women's role in society was
still tied to her reproductive capacity. It was
every American woman's duty during the 1950s
McCarthy era to be totally devoted to the family
and repopulate the nation (Adams 1960). The
empty nest problem occurred when these children
were grown and left home. Once children were
independent, women would experience the
syndrome of feeling unneeded, unnecessary and
would likely suffer from depression, low self-
esteem and psychosis. This concept implied that
mothering was the one of the main roles a
woman had in Western society.
Scientific/medical explanations were used to
validate and justify cultural norms and values
which rein scribed gender subordination for
women in our society.
The negative views regarding the
maturing female body coincided, more or less,
with the second wave of feminism in America.
At the same time that women were 'burning their
bras' in the United States fighting for gender
equality within the work force and within
American society, biomedical discourse focused
its attention on the maturing female body. It
was much easier to prevent older women who
were suffering from the debilitating physical and
psychological effects from an unstable,
fluctuating hormonal disease like menopause,
from re-entering the work force after the children
were grown and gone, than radical young
feminists. Although many feminist studies
focus on the power of older women, biomedical
discourse supported the idea that as women grew
older the loss of bodily function and mental
acuity was inevitable. The only thing that mid-
life women could hope for was medicated bliss.
A second spin off from the menopause
myth was the linkage between the benefits of
estrogen and coronary disease. For over two
decades it has been reported in the popular press
that heart disease has been the number one cause
of death in our affluent society affecting men
more commonly than women. Tunstall-Padoe
challenged the assumption that the risk of heart
disease in women increased post-menopause. He
argued that, "there is a myth that risk in women
is held low only until menopause, around age 50
years, when it rebounds, equaling, and later
surpassing that in men" (Tunstall-Pedoe
1998: 1425). This myth is based primarily on
"circumstantial evidence ... from studies of
women with artificial or premature menopause ...
to be at a greater risk than menstruating women
of the same age; from studies of the changes in
lipids ... and fmally from observational studies
on the apparent protective effects .... of HRT"
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(Tunstall-Pedoe 1998: 1425). He suggested that
the assumed observational coronary benefits
from HRT created, "a professional (prescribers)
and commercial (suppliers) lobby to perpetuate
the menopause myth, recommending HRT on
epidemiological grounds" (Tunstall-Pedoe
1998:1425). His research concluded that, "in
contradiction to the myth ... there is no rebound
acceleration in risk in women at or after age 50
years, there is no closing of the gap between the
sexes, which continues to widen, and no age at
which risk in the two sexes is the same"
(Tunstall-Pedoe 1998:1426). Biomedical
discourse swirled around the protective hormonal
cardiac benefits for women, however, this
discourse omitted men in our society who have a
higher death rate from coronary disease than
women, but who been studied to 'death' in terms
of coronary heart disease, unlike women.
Wonder Drug Hiccups
A minor snag in the promotion of HRT
as a viable treatment for all menopausal women
occurred in the mid 1970s. Four separate studies
linked estrogen replacement therapy with an
increase risk of endometrium cancer in women
with a uterus. By 1975, "hormone therapy
prescriptions peaked at 30 million [dollars]"
before the wonder drug hiccup caused sales to
plummet to "approximately 15 million in the
early 1980s " (Hersh, et al. 2004:47). Instead of
discontinuing estrogen therapy for women
undergoing 'natural' menopause, that is, women
with a uterus, the rationale was that "this cancer
could be prevented by antagonizing the estrogen
with a progestin, and several estrogen plus
progestin combinations were explored in the
search for one that preserved the benefits of
estrogen" (Hulley and Grady 2004: 1769, my
emphasis). The underlying medical and cultural
assumption was that "the female body will be
unable to attain its average life expectancy in
reasonably good health unless it is regularly
fueled with hormones"(Lock 1993:337) After
the addition of progestin to the hormonal
cocktail, ALL women, those with a uterus and
those without a uterus, could benefit from
continuous drug therapy for the rest of their
lives.
Solving The "Global Woman Problem"
Coinciding with plummeting
pharmaceutical sales and loss of revenue, in
1981, the World Health Organization, as a
political body, asserted itself the ultimate
rational, scientific, objective, authoritarian voice
over the female body by declaring menopause an
'estrogen-deficiency disease'. Male-stream
biomedical misconceptions regarding women's
bodies as diseased bodies were solidified and
extended universally to ALL women right
around the globe (WHO, 1980). Foucault's
notion of biopower focuses on the institutional
and state controlled power over populations with
the body as a site of contention (Foucault 1990).
By defming medical terms, providing a
diagnosis, outlining menopausal symptoms,
promoting HRT as an effective treatment,
outlining screening protocols, suggesting
behavioral changes and considering surgical
intervention, the World Health Organization
actually increased regulations and tightened the
disciplinary regime regarding women's bodies.
Margaret Lock argued that, "the medicalized
body (is) a manifestation of the potent, never
settled, partially disguised political contests that
contribute to the way in which the female body is
'seen' and interpreted" (Lock 1993:331).
Menopause continued to be viewed as a
physiological crisis in need of constant
monitoring and self-surveillance to measure up
to the 1980s model of the ideal woman that was
young, physically fit, feminine and fertile.
Women's bodies became regulated like never
before!
Following suit, in 1989, the American
College of Obstetrics and Gynecology,
"recommended that every women be considered
for HRT" (Barbre 2003:279). Barbre notes that
"numerous medical and scientific experts and
commercial drug companies" suggested that
hormone therapy was not only useful in
preventing a variety of symptoms associated with
menopause but, more importantly, HRT was
promoted as a prophylactic measure in
preventing diseases (Barbre 2003:279). In the
same year, Dr. Robert G. Wells wrote, "With so
many benefits and virtually no dangers, it now
seems reasonable to recommend that all post-
menopausal women -- regardless of age or
menopausal symptoms -- seriously be considered
for hormone replacement therapy" (Wells cited
in Barbre 2003:279). Pharmaceutical sales
climbed to "36 million in 1992" (Hersh, et al.
2004:47). Pharmaceutical promotional
campaigns and "designer" hormones in the
1990s, produced an increase in the prescriptions
of hormones "by 57% from 58 million in 1995 to
91 million in 200 I, and annualized to 89 million
for January through June 2002" (Hersh, et al.
2004:49). Hormone replacement therapy was
one of the most promoted pharmaceutical
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Debunking Pseudoscience: The Women's
Health Initiative Study
The Women's Health Initiative (WHI)
study which commenced in 1991, was designed
as a fifteen year research program to address the
effects of hormone therapy in relation to
cardiovascular disease, cancer and osteoporosis
in postmenopausal women. More than 160,000
generally healthy women, aged 50 - 75, took
part in the study which consisted of several
different clinic trials. The hormone trial carried
out two types of studies: estrogen plus progestin,
for women with a uterus, and estrogen alone, for
women without a uterus. Women were randomly
chosen to take a placebo or the correct hormone
supplement. The key focus of these studies was
to observe the effects of HR T on cardiovascular
disease in postmenopausal women (WHI
website).
The estrogen plus progestin study was
stopped in July 2002, after 5.6 years due to an
increase risk of breast cancer in the study group.
The summary of results regarding the estrogen
plus progestin as compared to the placebo
showed an increase in coronary deaths, an
increase in cardiovascular accidents, double the
risk of venous thrombosis, an increased risk of
breast cancer, and an increased risk of
developing cognitive impairment and dementia.
Estrogen plus progestin appears to decrease the
risk of colorectal cancer and decrease the number
of fractures women experienced. The estrogen
alone study was stopped in March 2004, after 6.8
years follow-up and women in the study were
asked to stop taking their study pills because the
risks outweighed the benefits. The summary of
the estrogen alone study revealed no difference
in risk for heart attacks and colorectal cancer.
However, the study did show an increased risk of
cardiovascular accidents, an increased risk of
venous thrombosis, and an increased risk of
dementia. Questions still remain unanswered
regarding the effects on breast cancer (WHI
website).
The WHI study revealed two things;
first, that decreasing levels of estrogen in post
menopausal women is not related to heart disease
as observed in the placebo group; and secondly,
that use of pharmaceutical hormones, estrogen
alone and estrogen plus progestin, administered
to post menopausal women, actually contributes
to a variety of illnesses such as, cardiovascular
disease, venous thrombosis, cancer and
dementia. Some wonder drug!
Deconstructing the Menopause Myth
The socio-economic fall-out from the
harmful results of this study resulted in a
decrease in the pharmaceutical promotion of
HRT, a decrease in physicians' prescription rate
and women's personal agency caused the sales of
hormonal drugs to plummet (Majumdar, et aI,
2004). By the year 2003, "HRT prescriptions
declined to 57 million, from 89 million the year
before" (Hersh, et al. 2004:50). Several
physicians have admitted that, "many studies
have documented that patterns of physician
practice are often more aligned with promotional
messages than with scientific evidence"
(Majumdar, et aI, 2004: 1983). The research
fmdings suggest, "that sustained promotional
efforts prior to the WHI estrogen plus progestin
study may have fostered the practice of hormone
therapy prescribing in the United States"
(Majumdar, et aI, 2004: 1987). This suggests that
economic profits outweigh women's health and
well-being in Western capitalistic societies.
The participants of the WHI study were
ask to stop taking their hormones, both the
estrogen plus progestin and the estrogen alone
group because the risks outweighed the benefits.
Exactly what benefits does HRT provide to
women who are experiencing vasomotor
symptoms related to menopause? The FDA
states that, "These products are approved
therapies for relief from moderate to severe hot
flashes and symptoms of vulvar and vaginal
atrophy ... to be used at the lowest doses for the
shortest duration needed to achieve treatment
goals" (FDA News Website). What exactly is
the safest, lowest possible dose to use? And how
long is too long? A month? Ten years? A life
time? No study has been done to determine the
appropriate dose and duration for safe hormone
replacement. Anne Fausto-Sterling writes that,
"hot flashes and vaginal dryness are the only
c1imateric-associated changes for which estrogen
unambiguously offers relief' (Fausto-Sterling,
1999: 174). But there is a slight catch, "although
estrogen does stop the hot flashes, its effects are
only temporary; remove the estrogen and the
flashes return" (Fausto-Sterling, 1999: 174). So
women have the option of 'treating' hot flashes
by a) accepting the surges of heat as a normal
physiological process, or b) taking estrogen for
the rest of their lives. Fausto-Sterling notes that
in time hormonal fluctuations level out and hot
flashes subside naturally.
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In October 2004, I attended a Heart and
Stroke Foundation: HeartSmart Women's
Taskforce presentation in Brantford, Ontario on
the results of the WHI and what these results
mean to menopausal women. It is unclear to me
why menopause continues to be associated with
the Heart and Stroke Foundation since the WHI
found no association between menopause and
heart disease. There were approximately 200
women attending this presentation sponsored by
Dell Pharmacy. A physician gave a presentation
regarding heart disease and menopause, followed
by a pharmacist who spoke about understanding
HRT and exploring alternative herbal remedies
for vasomotor symptoms. Circulating within this
medical discourse was idea that the results of the
WHI were statistically insignificant to the
individual woman, implying that being stricken
with a heart attack or a stroke was as likely to
happen as winning a lottery - a game of Russian
roulette. The central message was that women
should take responsibility for their own health
risks and were encouraged to "know their
numbers." An increase in body self-surveillance
and body policing was advocated; know your
blood pressure, your BMI, your cholesterol
levels, your blood glucose level, and maintain a
waist circumference less than 35 inches.
Women were encouraged to exercise for 30
minutes at least three times per week, stop
smoking, eat a low saturated fat, high fibre diet,
and visit their doctor for more in depth, personal
assessment and an individualized form of
treatment.
During this presentation, I noticed that
pharmaceutical companies switched tactics by
promoting vaginal estrogen creams to prevent the
new 'danger' of vulvar and vaginal atrophy.
Even well into old age, biomedical discourse
focuses on keeping vulvar and vaginal atrophy at
bay to .preserve that ever receptive, sexually
available female body for penile penetration.
This notion reinscribes heteronormative (man
and woman) sexual roles and gender
performance that reinforce patriarchal ideology
concerning women as the sexually receptive
member of the species.
A recent corporate strategy of the Dell
pharmaceutical company has been to certify and
hire 'Certified Menopause Practitioners' for
each pharmacy location to provide a personal,
individualized health profile for each woman
during a half hour consultation, for a fee of
$45.00. Sacred biomedical knowledge and
privileged information about women's bodies is
sold like a commodity. This practice elides the
fact that pharmaceutical companies are shaping
cultural practices within our society by deciding
what women need to purchase in order to stay
healthy. This practice also discriminates against
low income women who cannot afford this
service and women who are unaware that this
information is withheld. Sandra Lee Bartky
suggests that this practice reinforces
subordination of women because it is,
"orientated toward the production of isolated and
self-policing subjects" (Bartley 1997: 148).
Current biomedical discourse reconfirms and
reinscribes the female body as the pathological
body, the body in constant need of vigilant
monitoring and surveillance.
Conclusion
Many women all over the world from
different cultures find the cessation of menses a
pleasant and empowering experience (Fausto-
Sterling, 1999). In Western culture, the
medicalization of women's reproductive
capabilities have traditionally been used to
justify social/political/economic injustices and
inequalities faced by women in our patriarchal
society. During the 19th century, Victorian
women's subjectivity was constructed around
maladies of the reproductive organs, and
treatment consisted of social/physical/emotional
domestication and a life devoted to subservience.
By the mid 1960s, the cessation of menses was
rhetorically reconfigured into an 'estrogen
deficiency disease' and pharmaceutical chemical
compounds were medically and socially justified
to control the hormonal fluctuations experienced
by mid-life women. Today, women are being
encouraged to take control over their own health.
How ironic, we are being given supervised
autonomy over our own medicalized bodies!
The problem with the recent surge of
biomedical discourse surrounding menopause,
especially after the negative results from the
WHI study, is that women's subjectivity
continues to be constructed as a pathology of the
reproductive cycle in need of medicalization,
surveillance and discipline. Hormonal
supplements chemically restrain the aging female
body and preserve it, pickled in the perpetual
state of youth and beauty, thus conforming to the
patriarchal defmition of femininity. Women are
not allowed to grow old gracefully, the old
patriarchal fears of the elderly, wicked hag
prevail. Biomedicine as an institution of power
perpetuates structural violence against women by
reinforcing gender ideologies that sustain the
notion that women's reproductive cycle is central
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to women's sense of self identity. How can
Western women feel good about the cessation of
menses in mid-life when this contradicts the
Western idealized notion of the young and fertile
woman? What is it about non-bleeding, non-
breeding women that frightens the technocratic
culture of Western biomedicine? As women, we
must discipline our aging bodies to be healthy,
thin, youthful and continuously sexually
receptive. Foucault argued that, "discipline
produces subjected and practised bodies, 'docile'
bodies" (Foucault, 1995:138). However, I
would argue that although biomedicine as an
institution of power does produce a medicalized
subjectivity for women to practice and perform,
women are not docile bodies.
Many of the research papers reported a
high degree of non compliance in the Women's
Health Initiative HRT studies. Many women
chose not to take their hormones for the duration
of the study: they were the lucky ones. Allow
me to explain. The results of the WHI study on
hormone replacement therapy revealed that; a)
estrogen plus progestin and estrogen alone are
both associated with an increased risk of a host
of diseases including; breast cancer, coronary
deaths, cardiovascular accidents, venous
thrombosis and dementia; b) that fluctuating
levels of hormones in post-menopausal women is
NOT related to an increase in heart disease as
observed in the placebo group for both trails; and
[mally c) that pharmaceutical companies are
shaping cultural norms by targeting women in
their promotional campaigns, and driving the
pattern of physician practice. Seeking to turn a
profit, pharmaceutical companies continue to
promote their deadly chemical products with
little scientific justification at the expense of
women who have been historically
conceptualized as the diseased body in the eyes
of Western biomedicine.
Anthropological cross-cultural research
by Donna Davis, Margaret Lock and Anne
Fausto-Sterling, among others, reveals that ALL
women, in ALL societies, do not view
menopause as a pathology of the body in need of
medication. In many societies around the world
women gain social status when they stop
menstruating. Women's bodies are not diseased
by nature: pathology is the by-product of
Western biomedical discourse. What right do
pharmaceutical companies and the discipline of
biomedicine have in monopolizing the discourse
regarding women's bodies and embodied
experiences? It's time to reject the medicalized
construct of the female body created by the
institution of biomedicine and reclaim our right
to experience hot flashes as surges of
empowerment and celebrate the cessation of
menses like millions of women in different
cultures around the world.
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